NCT07323641
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07323641
Title Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.